(Q95794110)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

review article

1 reference

title

Fenofibrate: a review of its use in dyslipidaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1

Kate McKeage

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

author name string

Gillian M Keating

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

publication date

1 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

page(s)

1917-1946

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

30 May 2020

cites work

1 reference

12 December 2020

Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics

1 reference

12 December 2020

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

12 December 2020

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

1 reference

12 December 2020

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

1 reference

12 December 2020

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation

1 reference

12 December 2020

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

1 reference

12 December 2020

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

12 December 2020

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

1 reference

12 December 2020

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

1 reference

12 December 2020

PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation

1 reference

12 December 2020

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy

1 reference

12 December 2020

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

12 December 2020

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

1 reference

12 December 2020

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

12 December 2020

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study

1 reference

12 December 2020

Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective

1 reference

12 December 2020

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

1 reference

12 December 2020

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study

1 reference

12 December 2020

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

12 December 2020

Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes

1 reference

12 December 2020

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

1 reference

12 December 2020

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

1 reference

12 December 2020

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering

1 reference

12 December 2020

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease

1 reference

12 December 2020

Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate

1 reference

12 December 2020

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

1 reference

12 December 2020

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients

1 reference

12 December 2020

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

1 reference

12 December 2020

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study

1 reference

12 December 2020

Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia

1 reference

12 December 2020

Fenofibrate inhibits angiogenesis in vitro and in vivo

1 reference

12 December 2020

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

1 reference

12 December 2020

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

1 reference

12 December 2020

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

1 reference

12 December 2020

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

12 December 2020

Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

1 reference

12 December 2020

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia

1 reference

12 December 2020

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

1 reference

12 December 2020

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.

1 reference

12 December 2020

Reducing residual risk for patients on statin therapy: the potential role of combination therapy

1 reference

12 December 2020

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

1 reference

12 December 2020

AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

1 reference

12 December 2020

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

1 reference

12 December 2020

Pharmacoepidemiology safety study of fibrate and statin concomitant therapy

1 reference

12 December 2020

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

1 reference

12 December 2020

Lipid-lowering drugs and homocysteine

1 reference

12 December 2020

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

12 December 2020

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

1 reference

12 December 2020

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

1 reference

12 December 2020

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

12 December 2020

Safety considerations with fibrate therapy

1 reference

12 December 2020

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

1 reference

12 December 2020

A new formulation of fenofibrate: suprabioavailable tablets

1 reference

12 December 2020

Effects of fenofibrate and gemfibrozil on plasma homocysteine

1 reference

12 December 2020

The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia

1 reference

12 December 2020

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

1 reference

12 December 2020

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

1 reference

12 December 2020

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism

1 reference

12 December 2020

Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function

1 reference

12 December 2020

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

1 reference

12 December 2020

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

1 reference

12 December 2020

Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study

1 reference

12 December 2020

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

1 reference

12 December 2020

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

12 December 2020

The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.

1 reference

12 December 2020

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

1 reference

12 December 2020

Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia

1 reference

12 December 2020

Advances in the medical treatment of diabetic retinopathy

1 reference

12 December 2020

Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia

1 reference

12 December 2020

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

12 December 2020

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

12 December 2020

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

1 reference

12 December 2020

Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2

1 reference

12 December 2020

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

1 reference

12 December 2020

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

1 reference

12 December 2020

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

1 reference

12 December 2020

Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

1 reference

12 December 2020

Preventing diabetic complications: a primary care perspective

1 reference

12 December 2020

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

1 reference

12 December 2020

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

1 reference

12 December 2020

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

1 reference

12 December 2020

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

1 reference

12 December 2020

Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials

1 reference

12 December 2020

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

1 reference

12 December 2020

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

1 reference

12 December 2020

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

1 reference

12 December 2020

The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia

1 reference

12 December 2020

Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia

1 reference

12 December 2020

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

1 reference

12 December 2020

Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

1 reference

12 December 2020

Fenofibrate improves microcirculation in patients with hyperlipidemia

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

12 December 2020

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

1 reference

12 December 2020

Monocyte suppressing action of fenofibrate

1 reference

12 December 2020

Effects of medical therapies on retinopathy progression in type 2 diabetes

1 reference

12 December 2020

The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

1 reference

12 December 2020

Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.

1 reference

12 December 2020

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

1 reference

12 December 2020

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

12 December 2020

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

1 reference

12 December 2020

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

1 reference

12 December 2020

Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

1 reference

12 December 2020

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action

1 reference

12 December 2020

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

1 reference

12 December 2020

Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multic

1 reference

12 December 2020

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials

1 reference

12 December 2020

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

12 December 2020

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

12 December 2020

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

1 reference

12 December 2020

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

1 reference

12 December 2020

Peroxisome proliferator-activated receptors, orphans with ligands and functions

1 reference

12 December 2020

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

1 reference

12 December 2020

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

12 December 2020

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

1 reference

12 December 2020

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia

1 reference

12 December 2020

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

1 reference

12 December 2020

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

1 reference

12 December 2020

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

1 reference

12 December 2020

Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective

1 reference

12 December 2020

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).

1 reference

12 December 2020

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

1 reference

12 December 2020

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

1 reference

12 December 2020

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels

1 reference

12 December 2020

10.2165/11208090-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21942979%20AND%20SRC:MED&resulttype=core&format=json

30 May 2020

1 reference